Evaluation of (1 → 3)-β-D-glucan assay for diagnosing paracoccidioidomycosis.
Adolescent
Adult
Aged
Antibodies, Fungal
/ blood
Antifungal Agents
/ therapeutic use
Antigens, Fungal
/ immunology
Child
Child, Preschool
Enzyme-Linked Immunosorbent Assay
/ methods
Female
Glucans
/ immunology
Humans
Infant
Infant, Newborn
Latin America
Male
Middle Aged
Paracoccidioides
/ immunology
Paracoccidioidomycosis
/ diagnosis
Young Adult
(1 → 3)-β-D-glucan assay
Paracoccidioidomycosis
antifungal therapy
endemic mycosis
fungal biomarker
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
21
03
2019
revised:
12
09
2019
accepted:
13
09
2019
pubmed:
19
9
2019
medline:
15
5
2020
entrez:
19
9
2019
Statut:
ppublish
Résumé
Paracoccidioidomycosis (PCM) is highly prevalent in Latin America, but no commercial system is available for diagnosing this endemic mycosis. To check the performance of (1 → 3)-β-D-glucan assay (BDG) for diagnosing PCM in 29 patients with proven fungal disease and compared with double immunodiffusion assay for detecting anti-Paracoccidioides antibodies. We selected 52 serum samples sequentially obtained from 29 patients with active PCM (12 chronic and 17 acute form). Samples were collected at baseline, and for 16 patients, additional serum levels were obtained after 3 and 6 months of antifungal treatment. Detection of BDG in serum was performed by using the Fungitell Despite exhibiting good sensitivity in the diagnosis of patients with PCM, we failed to demonstrate any correlation between the postdiagnosis kinetic profile of BDG serum levels and clinical response to antifungal therapy. This finding may be related to the maintenance of quiescent foci of fungal infection in several organs and tissues, a phenomenon that has been previously reported by other authors and helps to understand why so many relapses are documented in patients treated for short periods of time. Finally, we did not find any correlation between BDG quantification and specific anti-P brasiliensis antibodies serum titres in patients with PCM. In conclusion, BDG is detected in serum samples of most patients with PCM but is probably not useful for predicting clinical response to antifungal therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Paracoccidioidomycosis (PCM) is highly prevalent in Latin America, but no commercial system is available for diagnosing this endemic mycosis.
OBJECTIVES
OBJECTIVE
To check the performance of (1 → 3)-β-D-glucan assay (BDG) for diagnosing PCM in 29 patients with proven fungal disease and compared with double immunodiffusion assay for detecting anti-Paracoccidioides antibodies.
PATIENTS AND METHODS
METHODS
We selected 52 serum samples sequentially obtained from 29 patients with active PCM (12 chronic and 17 acute form). Samples were collected at baseline, and for 16 patients, additional serum levels were obtained after 3 and 6 months of antifungal treatment. Detection of BDG in serum was performed by using the Fungitell
RESULTS
RESULTS
Despite exhibiting good sensitivity in the diagnosis of patients with PCM, we failed to demonstrate any correlation between the postdiagnosis kinetic profile of BDG serum levels and clinical response to antifungal therapy. This finding may be related to the maintenance of quiescent foci of fungal infection in several organs and tissues, a phenomenon that has been previously reported by other authors and helps to understand why so many relapses are documented in patients treated for short periods of time. Finally, we did not find any correlation between BDG quantification and specific anti-P brasiliensis antibodies serum titres in patients with PCM.
CONCLUSIONS
CONCLUSIONS
In conclusion, BDG is detected in serum samples of most patients with PCM but is probably not useful for predicting clinical response to antifungal therapy.
Substances chimiques
Antibodies, Fungal
0
Antifungal Agents
0
Antigens, Fungal
0
Glucans
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-42Subventions
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : 307510/2015-8
Informations de copyright
© 2019 Blackwell Verlag GmbH.
Références
Travassos LR, Taborda CP, Colombo AL. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther. 2008;6(2):251-262.
Mendes RP, Cavalcante RS, Marques SA, et al. Paracoccidioidomycosis: Current perspectives from Brazil. Open Microbiol J. 2017;11:224-282.
Shikanai-Yasuda MA, Mendes RP, Colombo AL, et al. Brazilian guidelines for the clinical management of paracoccidioidomycosis. Rev Soc Bras Med Trop. 2017;50(5):715-740.
Colombo AL, de Almeida Júnior JN, Slavin MA, Chen SC, Sorrell TC Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis. 2017;17(11):e344-e356.
Hoffmann ER, Daboit TC, Paskulin DD, et al. Disseminated histoplasmosis and AIDS: a prospective and multicentre study to evaluate the performance of different diagnostic tests. Mycoses. 2017;60(1):20-24.
Tone K, Umeda Y, Makimura K. Cross-reactivity in Cryptococcus antigen latex agglutination test in two commercial kits. Med Mycol. 2016;54(4):439-443.
Malo J, Holbrook E, Zangeneh T, et al. Enhanced antibody detection and diagnosis of coccidioidomycosis with the MiraVista IgG and IgM detection enzyme immunoassay. J Clin Microbiol. 2017;55(3):893-901.
Hage CA, Davis TE, Egan L, et al. Diagnosis of pulmonary histoplasmosis and blastomycosis by detection of antigen in bronchoalveolar lavage fluid using an improved second-generation enzyme-linked immunoassay. Respir Med. 2007;101(1):43-47.
Theel ES, Doernb CD. β-D-glucan testing is important for diagnosis of invasive fungal infections. J Clin Microbiol. 2013;51:3478-3483.
Girouard G, Lachance C, Pelletier R. Observations on (1-3)-beta-d-glucan detection as a diagnostic tool in endemic mycosis caused by Histoplasma or Blastomyces. J Med Microbiol. 2007;56:1001-1002.
de Camargo ZP, Unterkircher C, Campoy SP, Travassos LR. Production of Paracoccidioides brasiliensis exoantigens for immunodiffusion tests. J Clin Microbiol. 1988;26:2147-2151.
de Camargo ZP, Berzaghi R, Amaral CC, Silva S. Simplified method for producing Paracoccidioides brasiliensis exoantigens for use in immunodiffusion tests. Med Mycol. 2003;41:539-542.
Thompson GR, Bays DJ, Johnson SM, Cohen SH, Pappagianis D, Finkelman MA. Serum (1→3)-β-D- Glucan measurement in coccidioidomycosis. J Clin Microbiol. 2012;50(9):3060-3062.
Nakagawa Itano E, Uno J, Sano A, et al. Detection of the gp43 gene and (1→3)-β-D- Glucan of Paracoccidioides brasiliensis in the blood of experimentally infected mice. Nihon Ishinkin Gakkai Zasshi. 2002;43(1):29-35.
Vidal MS, Del Negro GM, Vicentini AP, et al. Serological diagnosis of paracoccidioidomycosis: high rate of inter-laboratorial variability among medical mycology reference centers. PLoS Negl Trop Dis. 2014;8(9):e3174.
Puccia R, Vallejo MC, Matsuo AL, Longo LV. The Paracoccidioides cell wall: past and present layers toward understanding interaction with the host. Front Microbiol. 2011;2:257.
Peres da Silva R, Heiss C, Black I, et al. Extracellular vesicles from Paracoccidioides pathogenic species transport polysaccharide and expose ligands for DC-SIGN receptors. Sci Rep. 2015;5:14213.
Koo S, Baden LR, Marty FM. Post-diagnostic Kinetics of the (1→3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis, and Pneumocystis jirovecii Pneumonia. Clin Microbiol Infect. 2012;18(5):E122-E127.
Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55(4):521-526.
Borges-Walmsley MI, Chen D, Shu X, Walmsley AR. The pathobiology of Paracoccidioides brasiliensis. Trends Microbiol. 2002;10(2):80-87.
Sylvestre TF, Franciscone Silva LR, Cavalcante Rde S, et al. Prevalence and serological diagnosis of relapse in paracoccidioidomycosis patients. PLoS Negl Trop Dis. 2014;8(5):e2834.